학술논문
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
Document Type
Article
Author
Source
In: Cancer Chemotherapy and Pharmacology . (Cancer Chemotherapy and Pharmacology, 1 August 2017, 80(2):307-315)
Subject
Language
English
ISSN
14320843
03445704
03445704